(2696.HK) announced that the new drug application (NDA) has been accepted by the National Medical Products Administration (NMPA) for its self-developed pertuzumab biosimilar HLX11, in combination with ...

with negative lymph nodes have a much higher risk of recurrence relative to tumors that are HER2-negative. Treatment with Herceptin (trastuzumab) can cut this risk by half. The pattern of breast ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker. The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of ...

which can be exploited to trigger receptor-mediated internalization and other downstream signal transduction.